A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 1/2 Terminated
2 enrolled
TSARINE
Phase 3 Terminated
13 enrolled
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Phase 3 Terminated
55 enrolled
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
34 enrolled 15 charts
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Phase 2 Terminated
17 enrolled
ELPIS
Phase 2 Terminated
5 enrolled 7 charts
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Phase 1 Terminated
1 enrolled
TrasTUCAN
Phase 2 Terminated
13 enrolled
BIS-Program
Phase 2 Terminated
33 enrolled
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Phase 1/2 Terminated
2 enrolled 6 charts
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Phase 1 Terminated
2 enrolled
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Phase 2 Terminated
17 enrolled 16 charts
TUGETHER
Phase 2 Terminated
31 enrolled
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled